<DOC>
	<DOCNO>NCT00170677</DOCNO>
	<brief_summary>Comparison topotecan weekly vs. topotecan day 1-5 . The compatibility activity examine .</brief_summary>
	<brief_title>Topotecan Weekly Versus Topotecan Day 1-5 Patient With Platin-resistant Ovarian Cancer</brief_title>
	<detailed_description>Topotecan belongs effective medicament therapy relapse platin-resistant ovarian cancer . Due low rate hematological toxicity grade 3 4 weekly application may improvement therapy . None randomise study exists compare weekly topotecan application application day 1-5 . This study compare two application regard : rate complete partial remission , rate toxicity , quality life , progression free survival , overall survival .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>patient histologicallyconfirmed ovarian cancer relapse within 6 month primary therapy primary therapy platin taxan ECOG 02 &gt; = 18 year leukocytes &gt; = 3.000/ µl platelet &gt; = 100.000/ µl neutrophil &gt; = 1.500/ µl write informed consent earlier topotecan therapy simultaneous plan radiotherapy secondary malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>